Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010;375:1721–8. https://doi.org/10.1016/S0140-6736(10)60482-5

Article  PubMed  PubMed Central  Google Scholar 

Weiss BM, Hebreo J, Cordaro DV, Roschewski MJ, Baker TP, Abbott KC, et al. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. J Clin Oncol. 2014;32:2699–704. https://doi.org/10.1200/JCO.2013.50.0892

Article  PubMed  PubMed Central  Google Scholar 

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48. https://doi.org/10.1016/S1470-2045(14)70442-5

Article  PubMed  Google Scholar 

Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Kumar S, Cerhan JR, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N. Engl J Med. 2018;378:241–9. https://doi.org/10.1056/NEJMoa1709974

Article  CAS  PubMed  PubMed Central  Google Scholar 

Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437–44.

Article  CAS  PubMed  Google Scholar 

Rindlisbacher B, Schild C, Egger F, Bacher VU, Pabst T, Leichtle A, et al. Serum free light chain assay: shift toward a higher kappa/lambda ratio. J Appl Lab Med. 2020;5:114–25. https://doi.org/10.1093/jalm.2019.029330

Article  PubMed  Google Scholar 

Singh G. Serum free light chain assay and kappa/lambda ratio performance in patients without monoclonal gammopathies: high false-positive rate. Am J Clin Pathol. 2016;146:207–14. https://doi.org/10.1093/ajcp/aqw099

Article  CAS  PubMed  Google Scholar 

Long TE, Indridason OS, Palsson R, Rognvaldsson S, Love TJ, Thorsteinsdottir S, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J. 2022;12:133 https://doi.org/10.1038/s41408-022-00732-3

Article  PubMed  PubMed Central  Google Scholar 

Long TE, Rögnvaldsson S, Thorsteinsdottir S, Sverrisdottir I, Eythorsson E, Indridason O, et al. Revised definition of free light chains in serum and light chain monoclonal gammopathy of undetermined significance: results of the istopmm study. Blood. 2023;142:535.

Article  Google Scholar 

Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812–7. https://doi.org/10.1182/blood-2005-03-1038

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl J Med. 2007;356:2582–90. https://doi.org/10.1056/NEJMoa070389

Article  CAS  PubMed  Google Scholar 

Mateos MV, Kumar S, Dimopoulos MA, Gonzalez-Calle V, Kastritis E, Hajek R, et al. International myeloma working group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10:102 https://doi.org/10.1038/s41408-020-00366-3

Article  PubMed  PubMed Central  Google Scholar 

Mateos MV, Hernandez MT, Giraldo P, de la Rubia J, de Arriba F, Lopez Corral L, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl J Med. 2013;369:438–47. https://doi.org/10.1056/NEJMoa1300439

Article  CAS  PubMed  Google Scholar 

Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38:1126–37. https://doi.org/10.1200/JCO.19.01740

Article  CAS  PubMed  Google Scholar 

Kyle RA, Larson DR, Therneau TM, Dispenzieri A, Melton LJ 3rd, et al. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematol. 2014;1:e28–e36. https://doi.org/10.1016/S2352-3026(14)70001-8

Article  PubMed  PubMed Central  Google Scholar 

Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, et al. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. Blood. 2016;128:2941–8. https://doi.org/10.1182/blood-2016-07-726778

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thorsteinsdóttir S, Oskarsson JT, Rögnvaldsson S, Long ÞE, Sverrisdottir IS, Gíslason GK, et al. P952: light chain smoldering multiple myeloma - the missing link: results from the screened istopmm study. HemaSphere. 2024;8:e1691 https://doi.org/10.1002/hem3.104

Article  Google Scholar 

Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110:2586–92. https://doi.org/10.1182/blood-2007-05-088443

Article  CAS  PubMed  Google Scholar 

Paiva B, Puig N, Cedena MT, Rosinol L, Cordon L, Vidriales MB, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38:784–92. https://doi.org/10.1200/JCO.19.01231

Article  CAS  PubMed  Google Scholar 

Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-Sanchez O, Bottcher S, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31:2094–103. https://doi.org/10.1038/leu.2017.29

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46. https://doi.org/10.1016/S1470-2045(16)30206-6

Article  PubMed  Google Scholar 

Perez-Escurza O, Flores-Montero J, Oskarsson J, Sanoja-Flores L, Del Pozo J, Lecrevisse Q, et al. Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study. Blood Cancer J. 2023;13:182 https://doi.org/10.1038/s41408-023-00944-1

Article  PubMed  PubMed Central  Google Scholar 

Gupta R, Jevremovic D, Mathew SJ, Kumar S. Multiparametric flow cytometry in the evaluation of plasma cell proliferative disorders: current paradigms for clinical practice. Clin Lymphoma Myeloma Leuk. 2024;24:e88–95. https://doi.org/10.1016/j.clml.2023.11.006

Article  CAS  PubMed  Google Scholar 

Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121–7. https://doi.org/10.1038/leu.2010.60

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006

Article  PubMed  PubMed Central  Google Scholar 

Rognvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, Oskarsson J, Petursdottir I, et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021;11:94 https://doi.org/10.1038/s41408-021-00480-w

Article  PubMed  PubMed Central  Google Scholar 

Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Bottcher S, Ritgen M, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26:1986–2010. https://doi.org/10.1038/leu.2012.122

Article  CAS